Stopped distributing investigational donor FMT material after the FDA ended enforcement discretion, ending the stool-bank distribution model.
SourceA nonprofit stool bank enabling access to fecal transplants.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
OpenBiome Foundation is a Massachusetts-based nonprofit that pioneered the first public stool bank in the U.S. and now focuses on expanding access to microbiome therapies, funding microbiome research, and sharing open-access tools/resources for patient care and discovery.
Primary product
Screened fecal microbiota transplantation (FMT) material and microbiome research/access programs
Founded
2012
Headquarters
Boston, Massachusetts, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Microbiome therapeutics / fecal microbiota transplantation (FMT) / stool bank
Offices
0 jobs at OpenBiome
Check back later for new openings
Business model
Stage
Seed
Total raised
$125K
Latest round
Venture Round · Jan 2022
Jan 2022
Aug 2020 · Y Combinator
Jan 2013 · The Draper Richards Kaplan Foundation
Jan 2013
Leadership
Chief Executive Officer
Paul Miller, Ph.D.
Chief Scientific Adviser
Colleen Kelly, MD
Chief Medical Adviser
Director of Operations
Clinical Research Adviser
Amanda Ceres
Senior Regulatory Adviser
Chief Operating Officer
Chair of the Board
Vice Chair of the Board
Treasurer
Board Member; General Counsel, Head of People
Mission-driven, cross-disciplinary nonprofit culture centered on scientists, clinicians, patient advocates, and microbiome enthusiasts; emphasizes collaboration across sectors and geographies, public-good impact, and open-access knowledge sharing.
Compensation
No public employee salary bands were found. A public donor-compensation paper says stool donors were historically paid $40 per processed donation, increased to $60 during the COVID-19 period.
Pricing
Nonprofit, grant/donation/earned-income funded; legacy FMT distribution to hospitals/clinics did not have a public list-price model.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M
Estimated monthly visits
4K
Traffic estimate as of Jul 2026
Stopped distributing investigational donor FMT material after the FDA ended enforcement discretion, ending the stool-bank distribution model.
SourceCEO messaging around the transition to the OpenBiome Foundation noted the FDA-driven shift forced difficult decisions, including downsizing, as the organization moved away from its prior stool-bank model.
SourceOpenBiome Foundation · Apr 2026
Official announcement naming new board leadership for a three-year term, with board officers from clinical, patient, technology, and financial backgrounds.
STAT · Mar 2026
Feature on the access challenges that emerged after OpenBiome stopped shipping donor material, and how FDA-approved C. diff drugs changed the treatment landscape.
OpenBiome Foundation · Jul 2025
Official launch/rebrand announcement describing the shift from FMT distributor to microbiome-science foundation.
OpenBiome Foundation / STAT · Jun 2025
OpenBiome reposted an op-ed arguing that access to fecal transplants was being constrained by regulatory and market changes.
OpenBiome Foundation
Official newsletter issue featuring CDC expert Dr. L. Clifford McDonald and OpenBiome’s ongoing microbiome/C. diff education work.